SUPN FY 2024 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$662M+8.9% YoY

Gross Profit

$584M88.2% margin

Operating Income

$82M12.3% margin

Net Income

$74M11.2% margin

EPS (Diluted)

$1.32

Cash Flow

Operating Cash Flow

$172M

Free Cash Flow

$171M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$332M

Stockholders' Equity

$1.0B

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$662M	$608M	+8.9%
Gross Profit	$584M	$524M	+11.5%
Operating Income	$82M	-$5M	+1649.9%
Net Income	$74M	$1M	+5512.8%